Evidence-based recommendations for the treatment of rheumatic and immunologic diseases with calcineurin inhibitors : a consensus statement
Calcineurin inhibitors (CNI), including oral cyclosporin A and tacrolimus, are intensive immunosuppressants that are extensively used in the treatment of rheumatic and immunologic diseases in China. CNI selectively inhibit the activation and proliferation of T lymphocytes and the transcription of cytokines [such as tumor necrosis factor-α, interleukin (IL)-6, and IL-17] through inhibiting the activation of calcineurin in cells and reducing the release of IL-2. To standardize the use of CNI in the field of rheumatic and immunologic diseases, this consensus statement was developed by the National Clinical Research Center for Dermatologic and Immunologic Diseases (Peking Union Medical College Hospital), in conjunction with the Chinese Association of Rheumatology and Immunology Physicians, the Chinese Research Hospital Association, the Rheumatology and Immunology Professional Committee, and the Chinese Association of Rehabilitation Medicine. The 2011 Oxford Centre for Evidence-Based Medicine Levels of Evidence was used to rate the quality of the evidence and the strength of the recommendations, and the RIGHT (Reporting Items for practice Guidelines in HealThcare) checklist was followed to report the consensus. The consensus offers recommendations addressing nine clinical challenges to Chinese clinicians. The primary objective of this consensus is to deliver scientific and detailed guidance on CNI for Chinese clinicians, and to improve the quality of patient-centered medical services.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
Zhonghua nei ke za zhi - 62(2023), 11 vom: 01. Nov., Seite 1266-1281 |
| Sprache: |
Chinesisch |
|---|
| Links: |
|---|
| Themen: |
Calcineurin Inhibitors |
|---|
| Anmerkungen: |
Date Completed 09.11.2023 Date Revised 09.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3760/cma.j.cn112138-20230416-00198 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36427252X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36427252X | ||
| 003 | DE-627 | ||
| 005 | 20231226095106.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.3760/cma.j.cn112138-20230416-00198 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1214.xml |
| 035 | |a (DE-627)NLM36427252X | ||
| 035 | |a (NLM)37935492 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 0 | |a National Clinical Research Center for Dematologic and Immunologic Diseases (Peking Union Medical College Hospital) |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evidence-based recommendations for the treatment of rheumatic and immunologic diseases with calcineurin inhibitors |b a consensus statement |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.11.2023 | ||
| 500 | |a Date Revised 09.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Calcineurin inhibitors (CNI), including oral cyclosporin A and tacrolimus, are intensive immunosuppressants that are extensively used in the treatment of rheumatic and immunologic diseases in China. CNI selectively inhibit the activation and proliferation of T lymphocytes and the transcription of cytokines [such as tumor necrosis factor-α, interleukin (IL)-6, and IL-17] through inhibiting the activation of calcineurin in cells and reducing the release of IL-2. To standardize the use of CNI in the field of rheumatic and immunologic diseases, this consensus statement was developed by the National Clinical Research Center for Dermatologic and Immunologic Diseases (Peking Union Medical College Hospital), in conjunction with the Chinese Association of Rheumatology and Immunology Physicians, the Chinese Research Hospital Association, the Rheumatology and Immunology Professional Committee, and the Chinese Association of Rehabilitation Medicine. The 2011 Oxford Centre for Evidence-Based Medicine Levels of Evidence was used to rate the quality of the evidence and the strength of the recommendations, and the RIGHT (Reporting Items for practice Guidelines in HealThcare) checklist was followed to report the consensus. The consensus offers recommendations addressing nine clinical challenges to Chinese clinicians. The primary objective of this consensus is to deliver scientific and detailed guidance on CNI for Chinese clinicians, and to improve the quality of patient-centered medical services | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Calcineurin Inhibitors |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Tacrolimus |2 NLM | |
| 650 | 7 | |a WM0HAQ4WNM |2 NLM | |
| 700 | 0 | |a Chinese Association of Rheumatology and Immunology Physicians |e verfasserin |4 aut | |
| 700 | 0 | |a Chinese Research Hospital Association, Rheumatology and Immunology Professional Committee |e verfasserin |4 aut | |
| 700 | 0 | |a Chinese Association of Rehabilitation Medicine, Rheumatology and Immunology Professional Committee |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhonghua nei ke za zhi |d 1957 |g 62(2023), 11 vom: 01. Nov., Seite 1266-1281 |w (DE-627)NLM000465526 |x 0578-1426 |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2023 |g number:11 |g day:01 |g month:11 |g pages:1266-1281 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3760/cma.j.cn112138-20230416-00198 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 62 |j 2023 |e 11 |b 01 |c 11 |h 1266-1281 | ||